• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

NIHR Oxford Health Biomedical Research Centre

Email Oxford Health BRC
MENUMENU
  • About
    • About
    • Management and core team
    • Our partners
    • Timeline of our key achievements
    • Core facilities
    • Oxford Health BRC Vacancies
    • Contact Us
  • Departments
    • NIHR Oxford Health Clinical Research Facility
    • Brain Health Centre
    • Oxford Precision Psychiatry Lab (OxPPL)
    • Oxford Dementia and Ageing Research (OxDARE)
    • Treatment Resistant Depression Clinic
    • Experimental Medicine and Industry Partnership (EMIP)
  • Research Themes
    • Summary
    • Better Sleep
    • Brain Technologies
    • Data Science
    • Dementia
    • Depression Therapeutics
    • Flourishing & Wellbeing
    • Mental Health in Development
    • Molecular Targets
    • Pain
    • Preventing Multiple Morbidities
    • Psychological Treatments
  • COVID-19 Research
    • Overview
    • News
    • COVID-19 & clinical management of mental health issues
  • News & Events
    • News
    • Training and Events
    • Psychiatry Department Seminars
  • Patients & Public
    • What is Patient and Public Involvement?
    • Key Contacts
    • Shape our research
    • Take part in our research
    • Resources for researchers
    • Resources for the public
    • Patient and Public Involvement Strategy
    • Young people’s involvement
  • EDI
    • Summary
    • Strategy
    • Diversity in Research Group
    • Key Contacts
  • Industry
    • Collaborate with Oxford Health
    • Who Do We Work With?
    • Industry Events
    • Further Information and Additional Resources
    • Contacts for Industry
  • Training Hub
You are here: Home / News / Research Themes / Brain Technologies / Blood clots during COVID-19 may be a cause of ongoing cognitive problems

Blood clots during COVID-19 may be a cause of ongoing cognitive problems

5th September 2023

High levels of two proteins at the time of COVID-19 have been found in patients who later experienced cognitive problems, including ‘brain fog’.

The findings give a major clue as to one cause of their symptoms: blood clots.

Dr Max Taquet and colleagues from the University of Oxford looked at blood tests from 1,837 people who had been hospitalised with COVID-19 to find potential proteins (biomarkers) associated with subsequent cognitive problems, with symptoms including serious and persistent problems with thinking, concentration and memory.

In a new paper published in Nature Medicine, they identified two separate profiles of biomarkers. The first was having a high level of a protein called fibrinogen, and the second was a raised level of a protein fragment called D-dimer. Other aspects of the profiles suggested they are likely to reflect blood clots. The main findings were replicated using electronic health records in a separate population.

Dr Taquet said: “Both fibrinogen and D-dimer are involved in blood clotting, and so the results support the hypothesis that blood clots are a cause of post-COVID cognitive problems. Fibrinogen may be directly acting on the brain and its blood vessels, whereas D-dimer often reflects blood clots in the lungs and the problems in the brain might be due to lack of oxygen. In line with this possibility, people who had high levels of D-dimer were not only at a higher risk of brain fog, but also at a higher risk of respiratory problems.

“The ultimate goal is to be able to prevent and reverse the cognitive problems seen in some people after COVID-19 infection. Although our results are a significant advance in understanding the basis of these symptoms, more research is needed into the causes and effects before we propose and test interventions.”

Professor Paul Harrison, from the University of Oxford who supervised the study, said: “Identifying predictors and possible mechanisms is a key step in understanding post-COVID brain fog. This study provides some significant clues.”

The participants involved in this research are part of the UKRI funded PHOSP-COVID (Post-hospitalisation COVID-19) study, led by University of Leicester. Their memory was assessed at six and 12 months after hospitalisation using both a formal test and by asking them their own subjective view about their memory.

A participant in the study said: “Since my illness I have been plagued by brain fog, concentration-induced fatigue, poor vocabulary, poor memory. I am unable to process the amount and scale of work that I would previously have done ‘stood on my head’.”

The study was funded by MQ Mental Health Research and the Wolfson Foundation, and supported by the National Institute for Health and Care Research (NIHR) Biomedical Research Centres in Leicester and Oxford Health.

Filed Under: Brain Technologies, COVID-19 research, News

Primary Sidebar

News Categories

  • News
    • Clinical Research Facility
    • COVID-19 research
      • Children, young people and family mental health
      • COVID-19 and psychiatric diagnosis
      • Online therapies and resources for clinicians
      • Patient and Public Involvement in the pandemic
      • PHOSP COVID
      • Vaccination and vaccine hesitancy
    • Research Themes
      • Better Sleep
      • Brain Technologies
      • Data Science
      • Dementia
      • Depression Therapeutics
      • Flourishing & Wellbeing
      • Mental Health in Development
      • Molecular Targets
      • Pain
      • Preventing Multiple Morbidities
      • Psychological Treatments
    • Training and Development

Footer

Follow us

  • LinkedIn
  • Twitter
  • YouTube

Improving brain health: the future in mind

The National Institute for Health and Care Research (NIHR) Biomedical Research Centre (BRC) is a partnership between Oxford Health NHS Foundation Trust and the University of Oxford.  We are part of the Oxford Academic Health Partners.
Oxford Academic Health Partners
  • Sitemap
  • Accessibility
  • Disclaimer
  • Cookies
  • Contact Us

© 2023 NIHR Oxford Health Biomedical Research Centre · Log in